Genfit S.A. (LON:0QT6)

Market Cap	137.24M
Revenue (ttm)	68.23M
Net Income (ttm)	18.88M
Shares Out	n/a
EPS (ttm)	0.37
PE Ratio	7.27
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	169
Average Volume	3,704
Open	3.083
Previous Close	3.089
Day's Range	3.084 - 3.174
52-Week Range	2.531 - 4.809
Beta	1.23
RSI	47.06
Earnings Date	Apr 24, 2025

About Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patien...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 159
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QT6

Financial Performance

In 2023, Genfit's revenue was 34.48 million, an increase of 31.38% compared to the previous year's 26.25 million. Losses were -28.89 million, 21.8% more than in 2022.

Financial numbers in EUR